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Abstract  
The International Human Epigenome Consortium (IHEC) coordinates the generation of a 
catalogue of high-resolution reference epigenomes of major primary human cell types.   The 
studies now presented (cell.com/XXXXXXX) highlight the coordinated achievements of IHEC 
teams to gather and interpret comprehensive epigenomic data sets to gain insights in the 
epigenetic control of cell states relevant for human health and disease. 
 
 
 
 
 
 
 
 
One of the great mysteries in developmental biology is how the same genome can be read by cellular 
machinery to generate the plethora of different cell types required for eukaryotic life. As appreciation 
grew for the central roles of transcriptional and epigenetic mechanisms in specification of cellular fates 
and functions, researchers around the world encouraged scientific funding agencies to develop an 
organized and standardized effort to exploit epigenomic assays to shed additional light on this process 
(Beck, Olek et al. 1999, Jones and Martienssen 2005, American Association for Cancer Research Human 
Epigenome Task and European Union 2008). 
 
In March 2009, leading scientists and international health research funding agency representatives were 
invited to a meeting in Bethesda (MD, USA) to gauge the level of interest in an international epigenomics 
project and to identify potential areas of focus.  This meeting, and a subsequent conference in January 
2010 in Paris (France) ultimately led to the creation of the International Human Epigenome Consortium 
(IHEC).   
 
The primary goals of IHEC are to coordinate the production of reference maps of human epigenomes for 
key cellular states relevant to health and diseases, to facilitate rapid distribution of the data to the 
research community, and to accelerate translation of this new knowledge to improve human health. A 
critical component of IHEC goals is to coordinate the development of common bioinformatics standards, 
data models and analytical tools to organize, integrate and display the epigenomic data generated.   
 
IHEC members all contribute to these primary goals, but they also have individual complementary goals 
such as developing new and improved ways to monitor or manipulate the epigenome, discovering new 
epigenomic mechanisms, training the next generation of epigenome researchers, exploring epigenomic 
features associated with disease states, and translating epigenomic discoveries into improvements to 
human health.  This is in keeping with the larger overarching vision of IHEC, which is to help address 
fundamental questions in how the genome and environment interact during development and aging, and 
how the epigenome influences health and disease.  
 
There are many strengths to a consortium model, bringing together research expertise and knowledge 
from across the world. These include the ability to implement and monitor high quality data and assay 
standards, maximize coverage of human cells and tissues while avoiding unnecessary duplication. 
Additionally this model helps harmonize data collection, management and analysis, to facilitate sharing 
and retrieval across countries, and provides open access to data and results.  IHEC provides a 
mechanism to facilitate communication among members, and provides a forum for coordination with the 
objective of maximizing efficiency among researchers working to understand, treat, and prevent 
diseases. 
 
Current full members of IHEC include: AMED CREST/IHEC Team Japan; DLR-PT for BMBF German 
Epigenome Programme DEEP; CIHR Canadian Epigenetics Environment, and Health Research 
Consortium (CEEHRC); European Union FP7 BLUEPRINT Project; Hong Kong Epigenomics Project; 
KNIH Korea Epigenome Project; NHGRI ENCODE; the NIH Roadmap Epigenomics Program; and the 
Singapore Epigenome Project (http://ihec-epigenomes.org/).   In the subsequent sections we overview 
experimental and computational tools developed by IHEC members and highlight key findings from a 
collection of recent publications from IHEC members.  
 
Indentifying heterogeneity in epigenomic measurements    
Cellular and allelic heterogeneity provides a significant challenge in the interpretation of epigenomic 
signatures that are typically derived from heterogeneous populations of millions of individual cells.  To 
address this challenge we have developed a series of molecular and computational approaches to 
deconvolute epigenomic signatures from heterogeneous populations.   Three independent strategies are 
presented to explore the heterogeneity at bivalent domains, a “poised state" marking important 
developmental genes characterized by an active (histone H3 lysine 4 trimethylation, H3K4me3) and a 
repressive (H3K27me3) mark on the same histone, and reveal that this combinatory epigenetic signature 
is both lost and gained at key regulatory genes during development (Hirst 2016, Kinkley, Helmuth et al. 
2016, Weiner, Lara-Astiaso et al. 2016).  Further these methods define previously undescribed co-
occurrence patterns of histone modifications on single nucleosomes and in relationship with enzyme 
accessibility of chromatin. To access the molecular information within a diversity of interacting cell types 
in complex tissues we developed in silico deconvolution methods that provide estimates of genomic CpG 
methylation and gene transcription within complex tissues, including solid tumors (Milosavljevic 2016) 
and hematological neoplasms (Martín-Subero 2016).  Finally, a meta-epigenomic approach that 
combines low-input and single-cell DNA methylation sequencing gave rise to a comprehensive map of 
the DNA methylation dynamics of human hematopoietic stem cell differentiation, experimentally and 
bioinformatically accounting for epigenomic heterogeneity (Farlik 2016). 
 
New computational tools bolster the utility of epigenome data for biology and medicine 
As of today, IHEC has generated over 7000 multi-dimensional datasets, which are publicly available 
through several channels. For specialized analyses, the raw data files containing personally identifiable 
data can be obtained under the controlled access scheme from dbGaP (NIH) and EGA (EBI). For 
common analyses not using any personally identifiable information, pre-processed data can be obtained 
from the unrestricted GEO (NIH) and ArrayExpress (EBI) repositories. To guide new users, IHEC has 
made a substantial investment into dedicated data access tools. The IHEC Data Portal 
(http://epigenomesportal.ca/ihec/) provides a comprehensive overview and single point of entry for 
accessing all IHEC reference epigenome data (Bourque 2016). This portal is complemented by tools for 
comparing epigenome data between cell types (Valencia 2016), for inferring epigenomic co-localization 
networks (Juan, Perner et al. 2016), for programmatic data access and filtering (Albrecht, List et al. 2016), 
for analyzing the results of epigenome-wide association studies (Breeze 2016), for detecting ChIP-seq 
peaks (Bourque 2016) and for predicting transcription factor binding (Schulz 2016). As part of IHEC’s 
mission to develop quality standards for epigenomic data, we have validated the accuracy of epigenome 
assays and proposed widely used quality standards for epigenome mapping (http://ihec-
epigenomes.org/). In addition, we investigated the effect of sequencing depth on the accuracy of whole 
genome bisulfite sequencing (Libertini, Heath et al. 2016, Libertini, Heath et al. 2016) and conducted a 
community-wide benchmarking study comparing locus-specific DNA methylation assays across 18 
laboratories in seven different countries, establishing that DNA methylation profiling is accurate and 
robust enough for use as a clinical biomarker (consortium 2016). Finally, two studies have started to 
connect epigenome regulation to the 3D structure of the nucleus, using high-resolution imaging (Larabell 
2016) as well as computational methods for integrative data analysis (Pancaldi, Carrillo-de-Santa-Pau et 
al. 2016). 
 
Epigenome analysis identifies pathways involved in cell fate determination and disease 
Recent technical advances allow the generation of genome-wide signatures for primary human cell types 
of increasingly narrowly defined biological properties. This provides new insights into the epigenetic and 
transcriptional basis of their differentiation capabilities, their responses to specific stimuli, and how these 
are altered in pathological conditions.  
 
Exciting new information can be retrieved from epigenomic differences between developmentally linked 
cell types, their inferred relationships, and the likely identity of chromatin and transcriptional regulators of 
their differentiation and developmental states (Arima and Sasaki 2016, Hirst and Eaves 2016, Polansky 
2016, Santana and Spicuglia 2016, Schuyler 2016, Wallner, Schroder et al. 2016).  Analysis of cells 
subjected to specific external stimuli shed new light on how environmental cues alter epigenomic states 
in both normal and pathological tissues (Arts 2016, Holland, Lowe et al. 2016, Polansky 2016, 
Stunnenberg 2016). Memory of such external exposures, coordinated at the chromatin level, can 
influence future behavior of the cell and susceptibility to disease under stress conditions. 
 
Epigenomic profiles of normal cell types also provide a valuable comparator for their counterparts in 
diseased tissues. Such comparisons have been performed in solid tumors such as breast cancer (Hirst 
and Eaves 2016) and extra-cranial malignant rhabdoid tumors (Chun, Lim et al. 2016), hematological 
neoplasms such as mantle cell lymphoma (Martín-Subero 2016) and chronic lymphocytic leukemia 
(Rendeiro, Schmidl et al. 2016).  These analyses have not only provided unprecedented insights into 
disease pathogenesis but have also enabled the stratification of diseases into novel clinico-biological 
subtypes. On the one hand, pathological tissues and cells exhibit epigenetic imprints of the 
developmental or differentiation stages from which they originate and, on the other hand, they acquire 
disease-specific epigenetic alterations. Exciting outcomes of these comparisons are the identification of 
disease-specific regulators and distant enhancers regulating oncogenes, the functional characterization 
of mutated/aberrantly expressed chromatin and transcriptional regulators, and how these might be 
profitably targeted by novel (Franci, Sarno et al. 2016) as well as existing therapies (Angela, Carafa et 
al. 2016, Chun, Lim et al. 2016, Martens 2016).  
 
These insights, together with the understanding of how immune cells alter their epigenomes in reaction 
to or to contribute to a diseased environment (Pagani 2016, Paul 2016, Santana and Spicuglia 2016, 
Stunnenberg 2016), and how the epigenomic changes are established by environmental cues (Holland, 
Lowe et al. 2016), will likely lead to new biomarkers for a better diagnosis and estimation of prognosis, 
as well as improved epi-drug based treatments and outcomes for a plethora of disease states. A present 
example of epigenomic analysis that may lead to testable clinical intervention is the reversal of endotoxin-
induced tolerance in macrophages(Stunnenberg 2016). 
 
The IHEC consortium is confident that the comprehensive analysis of epigenomes in health and disease 
will lead to a better understanding of how differentiation and stability of cellular phenotypes is controlled 
on a molecular level. By identification of novel biomarkers as well as targets for therapy, this will likely 
lead to improved treatment and outcomes in a variety of diseases. 
 
Epigenetic Marks Illuminate Effects of Noncoding DNA Variants in Disease 
A major challenge following the identification of DNA variants associated with different diseases is pinning 
down their effects, especially when they lie in noncoding regions of the genome.  A common mechanistic 
hypothesis is that the genetic variant affects the function of a cis-regulatory element and thereby the 
expression of a gene, which then influences the disease phenotype. To confirm such a hypothesis, it is 
important to characterize the molecular phenotypes that mediate the effect of genotype on disease. The 
IHEC studies capitalize on epigenomic information to address these questions, and several papers in the 
package take on the question of DNA variants in disease directly.  For example, a study of population 
variation in epigenetic states and gene expression in three human blood cell types showed that these 
molecular traits were often influenced by the same genetic variants in a coordinated manner, and 
underpinned hundreds of previously reported autoimmune disease associations (Soranzo 2016). Moving 
one step further along the path from genotype to phenotype, a related study catalogued population 
variation in cellular traits (36 blood-cell parameters) in a cohort of 173,480 individuals, and again detected 
correlations with genetic variation (Soranzo 2016). Notably, genetic loci associated with blood cell traits 
were frequently linked to epigenetic and transcriptomic traits and also to autoimmune conditions, 
schizophrenia and heart disease, potentially implying an etiological role for blood cell parameters. Along 
similar lines, correlations between genotype and histone acetylation variation in specific brain regions, 
termed histone acetylation QTLs (haQTLs), provided candidate regulatory variants at multiple loci 
associated with psychiatric diseases (Prabhakar 2016). 
 
The three-dimensional structure of chromosomes within the nucleus constitutes a key layer of epigenetic 
information, since it can generate diverse readouts from a constant genome sequence. From a practical 
standpoint, one can use maps of long-range loops between enhancers and promoters to determine which 
gene is regulated by a disease-associated noncoding variant. For example, maps of long-range contacts 
in 17 primary human blood cell types exhibited systemic variation across cell types and identified over 
2,500 potential disease genes when combined with a database of disease-associated variants (Fraser 
2016). Similarly, chromatin contact maps in 21 primary human tissues and cell types yielded a large 
compendium of candidate genes when combined with known disease-associated noncoding variants, 
and also revealed thousands of Frequently Interacting REgions (FIREs) with unusually high levels of 
long-range chromatin contacts (Ren 2016). Together, the studies in this section play a crucial role in 
using epigenetics to fill in the gaps between genotype and disease phenotype. 
 
Further Exploration 
A challenge faced by international consortia working with human data is the need to efficiently and openly 
share their data while sufficiently protecting the identity of participant donors from potential re-
identification. The response of the community has been to develop a “controlled access” governance 
framework to provide an additional level of privacy and security protection to the sharing of sensitive 
data. Our commentary (Joly 2016) presents the advantages and limitations, associated with controlled 
access, and introduces other, less demanding, data protection and security models including registered 
access, open consent and privacy enhancing technologies. Following a critical review of each of these 
alternative models, we conclude that, while all present specific advantages, none of them is currently 
ready to replace “controlled access”. However, as we become more familiar with data sharing, including 
its risks and benefits, it is hoped that the amount of procedural scrutiny around data sharing can be 
simplified. In this context the lighter protection and security models we describe here will take growing 
importance for data intensive health research. 
 
IHEC Looking Forward 
Epigenomic assays have revealed that selected subsets of regulatory elements in our genomic blueprints 
are read differently by gene expression machinery to maintain expression of the suites of genes needed 
for cellular functions.  Genome-wide epigenomic data for a diverse set of human cells and tissues also 
have great utility for generating hypotheses about the regulatory elements associated with complex 
human diseases.  These hypotheses can be tested by disease experts in the broad scientific community, 
for instance using CRISPR-based profiles to function (P2F) approaches for epigenome editing and 
screening (Beck 2016). 
Although IHEC is well on its way towards accomplishing its primary goals of generating high quality 
reference epigenomes and making them available to the scientific community, much more remains to be 
done.  As IHEC itself further develops, we anticipate shifting our focus towards a number of possible new 
directions. These include extensions of the previous goals as well as new opportunities to drive towards 
the overarching vision of improving human health including the integration of information from the 
environment and aging in the interpretation of cellular states.   Advances in technology will allow 
investigation of epigenomic changes in single cells rather than populations and the characterization of 
tissue/disease-linked heterogeneity.  Understanding natural and disease-linked variation in human 
epigenomes has already begun through IHEC, and will be expanded upon. Targeted editing of the 
epigenome to functionally validate regulatory mechanisms, has been gaining interest.   Deeper 
investigation of epigenomic changes during critical developmental periods and upon environmental 
exposure are natural extensions of current work. Integration of epigenomic and other –OMIC approaches 
(such as proteomics, metabolomics, transcriptomics and analyses of the microbiome) is already 
underway in several countries. In particular, there is considerable interest in integrating epigenomic, 
transcription factor binding, and expression data with chromatin conformation and sub-nuclear imaging 
information to develop a unified understanding of the 3D organization and regulatory dynamics of the 
nucleus.  There have been considerable new and exciting insights in the fields of cancer and inflammation 
in recent years, revealing primary epigenomic alterations associated with disease pathology. A key 
interest moving forward is to translate the knowledge gained through basic epigenomic investigations 
and resource generating consortia such as the IHEC to improve disease diagnosis, stratification and 
treatment through the continued development of epigenomic-based biomarkers and small molecule 
epigenetic therapeutics. These could be investigated in longitudinal and well-controlled intervention 
studies of epigenomics in relation to disease, aging, and environmental exposure. 
While not an exhaustive list, the above directions illustrate the wide range of potential opportunities 
provided by a coordinated, comprehensive assessment of epigenomic function. Future directions of the 
IHEC consortium will depend on the specific interests of the member projects, and an ongoing 
assessment of the best areas to continue to add value in epigenomic investigations. 
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